DEFYMED
Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a precise administration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were dev... eloped by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device. Defymed owns an exclusive technology and know-how which positions its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer management. Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey.
DEFYMED
Industry:
Diabetes Health Care Medical Device
Founded:
2011-03-07
Address:
Strasbourg, Alsace, France
Country:
France
Website Url:
http://www.defymed.com
Total Employee:
11+
Status:
Active
Contact:
+33390410446
Email Addresses:
[email protected]
Total Funding:
5.47 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Mobile Non Scaleable Content
Similar Organizations
Blackfynn
Blackfynn is a technology-driven, life-sciences company dedicated to transforming the way neurological diseases are diagnosed and treated.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Sensome
Sensome offers micro-sensor technology to turn medical devices into connected healthcare devices.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cap Innov'Est
Cap Innov'Est investment in Seed Round - Defymed
Cap Innov'Est
Cap Innov'Est investment in Seed Round - Defymed
Emertec
Emertec investment in Seed Round - Defymed
CeeD (Centre Européen d'étude du diabète)
CeeD (Centre Européen d'étude du diabète) investment in Seed Round - Defymed
CTTM
CTTM investment in Seed Round - Defymed
CeeD (Centre Européen d'étude du diabète)
CeeD (Centre Européen d'étude du diabète) investment in Seed Round - Defymed
Emertec
Emertec investment in Seed Round - Defymed
CeeD (Centre Européen d'étude du diabète)
CeeD (Centre Européen d'étude du diabète) investment in Seed Round - Defymed
CTTM
CTTM investment in Seed Round - Defymed
Statice
Statice investment in Seed Round - Defymed
Official Site Inspections
http://www.defymed.com
- Host name: 23-241-63-74.static.reverse.lstn.net
- IP address: 74.63.241.23
- Location: Dallas United States
- Latitude: 32.7767
- Longitude: -96.805
- Metro Code: 623
- Timezone: America/Chicago
- Postal: 75202
